HCG vs Kisspeptin-10
Human chorionic gonadotropin is a placental glycoprotein hormone that signals through the luteinizing hormone/chorionic gonadotropin receptor, acting directly on the gonad and reproducing LH activity with a much longer circulating half-life. Kisspeptin-10 is the C-terminal decapeptide of the KISS1 gene product and an agonist at KISS1R, acting several steps higher in the axis by driving release of endogenous gonadotropin-releasing hormone. The two are habitually set side by side because both raise gonadotropins, but they enter the same axis at opposite ends. Unusually for this category, direct evidence exists: several published experiments administered both compounds within one design, in women undergoing in vitro fertilisation, in rodents, in equines, in primates and in cultured Leydig and granulosa cells. An important caveat runs through the clinical half of that literature, because the human trigger studies used the longer isoform kisspeptin-54 rather than kisspeptin-10, and a published comparison of the two isoforms found their gonadotropin responses were not equivalent in duration.
They have been compared directly.
Both compounds have been given inside the same experiment on several occasions, though rarely in a design built to rank them. The largest clinical comparisons are retrospective and cohort analyses from Imperial College London and collaborating centres, in which women undergoing in vitro fertilisation were triggered with hCG, a GnRH agonist or kisspeptin. Abbara and colleagues reported that median ovarian volume and mean ascitic volume were largest after hCG and smallest after kisspeptin, and that the odds of an ovarian hyperstimulation syndrome diagnosis were far higher after hCG than after kisspeptin. A companion analysis of research cycles found that hCG concentrations peaked around a day after administration whereas luteinising hormone peaked within hours of kisspeptin, and that the endocrine response during oocyte maturation differed by trigger. Owens and colleagues compared granulosa lutein cells recovered from women who had received hCG, a GnRH agonist or kisspeptin-54, and found higher steroidogenic gene expression after kisspeptin without a change in markers associated with hyperstimulation. Every one of these human datasets used kisspeptin-54, not kisspeptin-10. Kisspeptin-10 itself appears in the animal and cell work: it raised serum testosterone in stallions, donkeys and mules alongside hCG and luteinising hormone, and it elevated hCG-stimulated testosterone in GnRH-receptor-blocked rhesus monkeys. Rodent trigger experiments, a mouse Leydig tumour cell bioassay and several Leydig cell culture studies applied kisspeptin and hCG to the same preparation, and repeatedly found that hCG acted on the gonad while kisspeptin did not, or did so only as a modulator of the hCG response.
The 21 studies that tested both
- 01Systematic review2021
Outcomes comparison of IVF/ICSI among different trigger methods for final oocyte maturation: A systematic review and meta-analysis
Zhang Y, et al. · FASEB J · systematic review and meta-analysis of randomised trials comparing GnRH agonist, kisspeptin, dual trigger and FSH co-trigger against conventional hCG trigger in IVF/ICSI; PROSPERO CRD42020194201
Randomised trials of four alternative trigger strategies were pooled against conventional hCG. Dual trigger was associated with more cumulus-oocyte complexes, more mature oocytes and more two-pronuclear oocytes than hCG, without a significant difference in pregnancy rate, and the risk of ovarian hyperstimulation syndrome did not differ significantly between the treatment groups and hCG in this analysis. Kisspeptin was one of the pooled comparators.
- 02Human clinical2018
Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment
Abbara A, et al. · Clin Endocrinol (Oxf) · retrospective single-centre cohort study in women at high risk of ovarian hyperstimulation syndrome triggered with hCG (n=40), GnRH agonist (n=99) or kisspeptin (n=122), 2013-2016
Median ovarian volume was largest after hCG, intermediate after GnRH agonist and smallest after kisspeptin, and mean ascitic volume followed the same order. Symptoms of ovarian hyperstimulation syndrome were most frequent after hCG and least frequent after kisspeptin, and the odds ratio for a diagnosis of the syndrome was 33.6 (95% CI 12.6-89.5) after hCG compared with kisspeptin. The kisspeptin administered was kisspeptin-54.
Reported safety finding. Ovarian hyperstimulation syndrome was diagnosed far more often after hCG trigger than after kisspeptin trigger in women already at high risk.
- 03Human clinical2020
Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment
Abbara A, et al. · Front Endocrinol (Lausanne) · retrospective cohort analysis of prospectively collected hormonal data from 499 research IVF cycles triggered with hCG, GnRH agonist or kisspeptin
The endocrine response during oocyte maturation differed markedly by trigger. hCG concentrations peaked approximately a day after administration, whereas luteinising hormone peaked within hours of GnRH agonist or kisspeptin. Progesterone rose sharply after every trigger and predicted the number of mature oocytes retrieved, but was positively associated with hCG concentration after hCG and negatively associated with the luteinising hormone rise after all three agents. The kisspeptin arm used kisspeptin-54.
- 04Human clinical2018
Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte
Abbara A, et al. · Front Endocrinol (Lausanne) · retrospective analysis of 449 women aged 18-38 triggered with hCG (n=161), GnRH agonist (n=165) or kisspeptin (n=173), using generalised linear regression and random forest models
Follicles measuring 12-19 mm on the morning of trigger contributed most of the mature oocytes retrieved after each of the three agents, indicating that this determinant of yield was shared rather than trigger-specific. The hCG and GnRH agonist data came from one centre and the kisspeptin data from another, and the kisspeptin administered was kisspeptin-54.
- 05Human clinical2018
The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function
Owens LA, et al. · Hum Reprod · 48 women undergoing IVF triggered with hCG (n=12), GnRH agonist (n=12) or kisspeptin-54 (n=24), with granulosa lutein cells subsequently cultured with kisspeptin or hCG in vitro; ClinicalTrials.gov NCT01667406
Granulosa lutein cells from women triggered with kisspeptin-54 showed higher expression of FSH receptor, LH/CG receptor, StAR, aromatase, 3-beta-hydroxysteroid dehydrogenase type 2, inhibin A and both oestrogen receptors than cells from women triggered with hCG or GnRH agonist, while markers associated with vascular permeability were unchanged. Applied directly to the cultured cells, hCG induced steroidogenic gene expression whereas kisspeptin-54 had no significant direct effect.
- 06Animal in vivo2017
Effect of kisspeptin-10, LH and hCG on serum testosterone concentrations in stallions, donkeys and mules
Akhtar RW, Shah SAH, Qureshi IZ · Theriogenology · male equines (stallions, donkeys, mules) in four groups of three, given intravenous saline, kisspeptin-10, hCG or LH with serial testosterone sampling to 240 minutes
Kisspeptin-10 and hCG each raised serum testosterone above pre-dose concentrations in stallions and donkeys, and both agents together with luteinising hormone raised testosterone in mules. Luteinising hormone produced the earliest rise, while the kisspeptin-10 and hCG responses appeared later in the sampling window. This is one of the few experiments in which kisspeptin-10 itself, rather than kisspeptin-54, was administered alongside hCG.
- 07Animal in vivo2014
Intratesticular action of kisspeptin in rhesus monkey (Macaca mulatta)
Irfan S, et al. · Andrologia · four adult male rhesus monkeys, intravenous human kisspeptin-10 with and without GnRH receptor antagonist pretreatment, compared against saline plus hCG
Kisspeptin-10 produced a single luteinising hormone pulse followed by a sustained rise in plasma testosterone, and that response was abolished when animals were pretreated with a GnRH receptor antagonist, confirming that the principal effect was upstream. In antagonist-pretreated animals, kisspeptin-10 nonetheless raised hCG-stimulated testosterone above saline plus hCG, which the authors described as a peripheral facet of kisspeptin signalling.
- 08Animal in vivo2023
Immunohistochemistry of Leukemia Inhibitory Factor and Integrin αVβ3 in Mouse Endometrium Following Kisspeptin-54 Ovulation Trigger
Abdelkareem AO, et al. · Reprod Sci · superovulated C57BL/6J female mice randomised to phosphate-buffered saline, hCG or kisspeptin-54 as ovulation trigger, five per group, with endometrial immunostaining on day 7
Leukemia inhibitory factor staining was higher in glandular epithelium and stromal cells after the kisspeptin-54 trigger than after placebo, and higher than after the hCG trigger in stromal cells. Integrin alphaVbeta3 staining was higher in stromal cells after kisspeptin-54 than after placebo. The authors stated that the findings had not been correlated with implantation or pregnancy outcomes. The peptide used was kisspeptin-54 rather than kisspeptin-10.
- 09Animal in vivo2022
Effects of intracerebroventricular and intravenous administration of Kisspeptin-54 and Gonadotropin-releasing hormone agonist in rats with ovarian hyperstimulation
Bilister Egilmez C, et al. · Neuropeptides · immature female rats, ovarian hyperstimulation induced with pregnant mare serum gonadotropin followed by hCG, then treated with kisspeptin-54 or GnRH agonist by intracerebroventricular or intravenous route
hCG was used to establish the hyperstimulation model and kisspeptin-54 was given afterwards as treatment. Both routes of kisspeptin-54 reduced ovarian immunoreactivity for VEGFa, IL-1 beta, TNF-alpha and MCP-1, and the intracerebroventricular route raised Kiss1R messenger RNA in ovary and hypothalamus. Ovarian weight was increased in the hyperstimulation and systemic GnRH agonist groups. The peptide used was kisspeptin-54 rather than kisspeptin-10.
- 10In vitro2023
Highly-Sensitive In Vitro Bioassays for FSH, TSH, PTH, Kp, and OT in Addition to LH in Mouse Leydig Tumor Cell
Klett D, et al. · Int J Mol Sci · mouse Leydig tumour cells transfected with several G protein-coupled receptors, including the human kisspeptin receptor, stimulated with LH or hCG alone and in combination with kisspeptin variants
In cells transfected with the human kisspeptin receptor, kisspeptin variants produced a dose-dependent synergy with a fixed concentration of luteinising hormone or hCG, whereas hCG alone drove the standard cyclic AMP response through the endogenous LH/CG receptor. The authors stated that a receptor-knockout cell line would be required before such bioassays could be considered specific.
- 11In vitro2013
Does Kisspeptin Signaling have a Role in the Testes?
Mei H, et al. · Front Endocrinol (Lausanne) · transgenic reporter mice for Kiss1 and Gpr54, immortalised MA-10 Leydig cells and seminiferous tubule explants challenged with kisspeptin or hCG
Kiss1 and Gpr54 reporter expression in mouse testis was restricted to haploid spermatids, and no kisspeptin protein was detected. Neither MA-10 Leydig cells nor seminiferous tubule explants responded to kisspeptin, while both responded appropriately to hCG, which the authors used to confirm the functional integrity of the preparations. They concluded that kisspeptin signalling had no significant role in mouse testis function.
- 12In vitro2017
Effect of kisspeptin challenge on testosterone and inhibin secretion from in vitro testicular tissue of adult male rhesus monkey (Macaca mulatta)
Tariq AR, Shabab M · Andrologia · cultured testicular fragments from five adult male rhesus monkeys incubated with graded kisspeptin concentrations, with hCG and FSH incubations as positive controls
Kisspeptin did not significantly raise testosterone or inhibin at any concentration tested, while hCG and FSH significantly increased hormone concentrations relative to basal conditions in the same preparations. The authors concluded that kisspeptin had no role in the direct testicular regulation of testosterone or inhibin release.
- 13In vitro2020
KISS1R signaling modulates gonadotropin sensitivity in mouse Leydig cell
Hsu MC, et al. · Reproduction · MA-10 mouse Leydig tumour cells with small interfering RNA knockdown of Kiss1r, assessed under basal and hCG-stimulated conditions
Knockdown of the kisspeptin receptor reduced progesterone production under both basal and hCG-stimulated conditions, accompanied by lower expression of the LH/choriogonadotropin receptor and StAR. The authors linked the result to the gonadotropin insensitivity and failure of hCG response reported in men carrying loss-of-function KISS1R mutations.
- 14In vitro2018
Effect of kisspeptin antagonist on goat in vitro Leydig cell steroidogenesis
Samir H, Nagaoka K, Watanabe G · Theriogenology · purified Leydig cells from five castrated Shiba goats cultured with graded concentrations of a kisspeptin receptor antagonist, with or without subsequent hCG stimulation
Kiss1 and GPR54 messenger RNA were more strongly expressed in hCG-treated wells than in untreated wells. The kisspeptin receptor antagonist reduced basal testosterone production and attenuated hCG-induced testosterone and oestradiol production, which the authors interpreted as evidence that endogenous kisspeptin signalling participates in the Leydig cell response to hCG.
- 15Systematic review2022
Diagnostic Value of Kisspeptin Levels on Early Pregnancy Outcome: a Systematic Review and Meta-analysis
Hu KL, et al. · Reprod Sci · systematic review of five studies with meta-analysis of three, comparing circulating kisspeptin against hCG for discriminating miscarriage from viable intrauterine pregnancy
Neither compound was administered; both were measured. Pooled kisspeptin measurement gave an area under the curve of 0.902 for distinguishing miscarriage from viable intrauterine pregnancy, against 0.834 for hCG, a difference of 0.09 (95% CI 0.02-0.16). The authors concluded that kisspeptin had comparable or higher accuracy than hCG after six weeks of gestation.
- 16Human clinical2021
Performance of plasma kisspeptin as a biomarker for miscarriage improves with gestational age during the first trimester
Abbara A, et al. · Fertil Steril · prospective nested case-control study, 95 women with miscarriage (173 samples) and 265 women with healthy pregnancies (557 samples), serial ultrasound and plasma sampling
Both molecules were measured rather than given. Gestation-adjusted plasma kisspeptin and beta-hCG were lower in pregnancies complicated by miscarriage, and the area under the curve for identifying miscarriage across the first trimester was 0.874 for kisspeptin, 0.859 for beta-hCG and 0.916 for the two markers summed. Kisspeptin performance improved with advancing gestation while beta-hCG performance worsened.
- 17Review2022
Use of kisspeptin to trigger oocyte maturation during in vitro fertilisation (IVF) treatment
Sharma B, et al. · Front Endocrinol (Lausanne) · narrative review of kisspeptin as an oocyte maturation trigger, set against hCG and GnRH agonist triggers
The review set out the case for triggering oocyte maturation through endogenous GnRH release rather than exogenous LH-receptor stimulation, summarised the phase 2 kisspeptin-54 trigger programme, and contrasted the shorter gonadotropin exposure it produced with the sustained receptor occupancy that follows hCG.
- 18Review2025
The Trigger in IVF Cycles: Molecular Pathways and Clinical Implications
Baldini GM, et al. · Int J Mol Sci · review of molecular pathways and clinical implications of trigger agents in IVF
The review compared trigger agents at the level of receptor signalling and clinical outcome, described hCG as the most widely used agent despite its association with ovarian hyperstimulation syndrome, and placed kisspeptin among the agents that have remained largely within research settings.
- 19Review2017
Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans
Kasum M, et al. · Gynecol Endocrinol · narrative review of kisspeptin as an oocyte maturation trigger relative to established agents
The review positioned kisspeptin against hCG and GnRH agonist triggers, described the short physiological luteinising hormone surge generated by kisspeptin as the proposed basis for its lower reported hyperstimulation risk, and noted that the supporting trials were small, single-centre and conducted with kisspeptin-54.
- 20Review2014
Pharmaceutical options for triggering of final oocyte maturation in ART
Castillo JC, Humaidan P, Bernabéu R · Biomed Res Int · review of pharmaceutical agents used to trigger final oocyte maturation in assisted reproduction
The review catalogued urinary and recombinant hCG, GnRH agonist, recombinant luteinising hormone and kisspeptin as trigger options, described the long half-life of hCG and the consequent sustained luteotrophic stimulus as the mechanism underlying its hyperstimulation risk, and treated kisspeptin as an experimental alternative at that time.
- 21Review2019
Advances in ovulation trigger strategies
Dosouto C, Haahr T, Humaidan P · Panminerva Med · review of ovulation trigger strategies in assisted reproduction
The review traced the shift from hCG-only triggering toward GnRH agonist, dual and adjunct strategies, and included kisspeptin among the newer agents under investigation, noting that its clinical evidence base at the time consisted of early-phase trials rather than comparative outcome trials.
Side by side.
| HCG | Kisspeptin-10 | |
|---|---|---|
| Evidence maturity | Approved drug | Early clinical |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 12 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A heterodimeric placental glycoprotein hormone sharing an alpha subunit with LH, FSH and TSH. The crystal structure published in 1994 showed a cystine-knot fold with a beta-subunit seatbelt segment holding the dimer together. | A ten-amino-acid C-terminal fragment of the KISS1 gene product, also published as human metastin 45-54. The parent peptide is endogenous, and the decapeptide is the shortest fragment retaining full receptor activity. |
| Mechanism as described in the literature | Acts at the bottom of the axis, binding the LH/chorionic gonadotropin receptor on Leydig and granulosa cells directly. Receptor-knockout mouse work indicates that LHCGR signalling is required for postnatal Leydig cell maturation, androgen production and completion of gametogenesis. | Acts at the top of the axis, binding KISS1R on hypothalamic GnRH neurons and triggering release of endogenous GnRH. The gonadal effect is therefore indirect, and it was abolished when GnRH receptors were blocked in the rhesus monkey experiments. |
| Size of the evidence base | Fifteen studies in this library, twelve of them systematic reviews, network meta-analyses or Cochrane reviews. The evidence base is large, long-established and dominated by randomised trials and their syntheses. | Sixteen studies in this library, twelve of them human clinical work. The volume is smaller and the designs are mostly acute single-centre administration experiments rather than outcome trials. |
| Best-characterised finding | Reliable triggering of final oocyte maturation and ovulation in assisted reproduction, and support of Leydig-cell testosterone production and spermatogenesis in male hypogonadotropic hypogonadism. | Dose-related, short-lived gonadotropin release after administration, with a response that is sexually dimorphic in humans and, in women, dependent on menstrual cycle phase. A direct comparison found kisspeptin-54 produced a more prolonged response than kisspeptin-10. |
| Human data | Extensive. Meta-analyses cover trigger selection in normal, high and poor responders, luteal-phase support, intrauterine instillation, insemination timing, spermatogenesis induction and pubertal induction. A 1995 criteria-based meta-analysis found no benefit over placebo for weight loss. | Present but early. Human work covers intravenous, subcutaneous and intranasal routes, hypoactive sexual desire disorder, food intake, precocious puberty diagnostics and IVF triggering, with few trials reporting live birth or sustained symptomatic change. Much of the clinical trigger work used kisspeptin-54 rather than kisspeptin-10. |
| Evidence maturity | Approved drug. Urinary-derived hCG and recombinant choriogonadotropin alfa hold marketing authorisations, and guideline and consensus documents adjudicate their use. | Early clinical. No kisspeptin peptide is approved as a medicine in any major jurisdiction, and long-term safety data are absent. |
| Safety signals reported | Ovarian hyperstimulation syndrome is the defining reported hazard, attributed to sustained LH-receptor occupancy from the long circulating half-life. In the high-risk cohort study the odds of a diagnosis were more than thirty-fold higher after hCG than after kisspeptin. | The reported signal is the absence of one in the studied setting: no moderate, severe or critical hyperstimulation was reported in the phase 2 kisspeptin trigger trials in women at high risk, and ovarian and ascitic volumes were smallest in the kisspeptin arm. Those data concern kisspeptin-54 and short exposure only. |
| Basis of most marketing claims | Extension of approved fertility and hypogonadism indications to testosterone recovery and weight management, the latter contradicted by the controlled trial evidence. | Extrapolation from acute gonadotropin-release experiments in healthy volunteers, and from clinical trigger studies conducted with the longer kisspeptin-54 isoform, to sustained testosterone or fertility outcomes that have not been measured for kisspeptin-10. |
And what it does not.
These two compounds have genuinely been given inside the same experiment, which is rare for this category, but the comparisons that exist were not designed to rank them. The clinical work consists of retrospective and cohort analyses of IVF triggering, and it points consistently in one direction: hCG produced larger ovaries, more ascites and far more diagnosed hyperstimulation than kisspeptin, while the endocrine profile after kisspeptin more closely resembled a physiological surge. Every one of those human datasets used kisspeptin-54, not the decapeptide sold as kisspeptin-10. Where kisspeptin-10 itself was administered alongside hCG, the setting was animal or cell culture, and the recurring result was that hCG acted directly on the gonad while kisspeptin-10 did not, raising testosterone only through an intact hypothalamic route. Nothing in the published record supports treating kisspeptin-10 as an interchangeable substitute for hCG in men, and no trial has compared the two on testosterone recovery, spermatogenesis or fertility outcomes. hCG has approval, guidelines and decades of randomised evidence behind it; kisspeptin-10 has neither approval nor a comparative outcome trial.
Common questions.
- Has any study given both hCG and kisspeptin-10 to the same subjects?
Not in humans. The human studies that administered both compounds within one design used kisspeptin-54, the longer circulating isoform, as the comparator against hCG in IVF triggering. Kisspeptin-10 was administered alongside hCG in an equine study measuring serum testosterone and in rhesus monkeys pretreated with a GnRH receptor antagonist, and it was applied with hCG to cultured Leydig and Leydig tumour cells. No published human experiment has given hCG and kisspeptin-10 to the same participants.
- Why does the difference between kisspeptin-54 and kisspeptin-10 matter when reading these comparisons?
Because the two isoforms did not behave identically in humans. A direct comparison in healthy men found that both raised gonadotropins but kisspeptin-54 produced a more prolonged response than the shorter-acting kisspeptin-10. The clinical trigger trials, the hyperstimulation cohort study and the granulosa cell work all used kisspeptin-54, so their findings describe a longer exposure profile than the decapeptide would produce. Transferring those results to kisspeptin-10 assumes an equivalence that the published comparison of the two isoforms did not demonstrate.
- What did the studies that applied both compounds to testicular tissue find?
They found a consistent separation of action. In cultured monkey testicular fragments, kisspeptin did not significantly change testosterone or inhibin at any concentration tested while hCG and FSH did, and the authors used the hCG response to confirm the tissue was functional. Mouse Leydig cells and seminiferous tubule explants likewise responded to hCG but not to kisspeptin. In knockdown work, removing the kisspeptin receptor reduced the progesterone response to hCG, which suggested a modulatory rather than a stimulatory role at the gonad.
- Do the ovarian hyperstimulation findings mean kisspeptin is the safer agent?
They describe one hazard in one setting. In women at high risk of hyperstimulation, ovarian volume, ascitic volume, symptom frequency and diagnosis rates were all lower after kisspeptin than after hCG, and the odds ratio for a diagnosis after hCG exceeded thirty. That study was retrospective, single-centre and conducted with kisspeptin-54. It does not address long-term safety, repeated exposure, use in men, or any endpoint outside assisted reproduction, and no kisspeptin peptide carries an approved safety label.
- How do the two compare as measurements rather than as treatments?
Both circulate in pregnancy and both have been evaluated as biomarkers. A prospective nested case-control study reported areas under the curve of 0.874 for plasma kisspeptin and 0.859 for beta-hCG in identifying miscarriage across the first trimester, rising to 0.916 for the two combined, with kisspeptin performing better as gestation advanced and beta-hCG worse. A meta-analysis reported a similar pattern. These are diagnostic comparisons in which nothing was administered, and they describe measurement accuracy rather than the effects of giving either peptide.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.